Central Trust Company’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$46.5M Buy
213,747
+1,153
+0.5% +$256K 0.92% 27
2025
Q4
$48.6M Sell
212,594
-3,755
-2% -$855K 0.95% 26
2025
Q3
$50.1M Sell
216,349
-1,989
-0.9% -$405K 1.05% 24
2025
Q2
$40.5M Sell
218,338
-11,458
-5% -$2.13M 0.94% 26
2025
Q1
$48.1M Sell
229,796
-2,634
-1% -$512K 1.18% 18
2024
Q4
$41.3M Buy
232,430
+3,105
+1% +$571K 1.01% 23
2024
Q3
$45.3M Sell
229,325
-4,709
-2% -$879K 1.06% 21
2024
Q2
$40.1M Sell
234,034
-5,766
-2% -$955K 0.98% 25
2024
Q1
$43.7M Sell
239,800
-8,229
-3% -$1.42M 1.09% 23
2023
Q4
$38.4M Sell
248,029
-1,978
-0.8% -$288K 1.02% 23
2023
Q3
$37.3M Sell
250,007
-3,271
-1% -$480K 1.07% 20
2023
Q2
$34.1M Sell
253,278
-4,849
-2% -$711K 0.95% 24
2023
Q1
$41.1M Sell
258,127
-2,071
-0.8% -$317K 1.2% 16
2022
Q4
$42.1M Sell
260,198
-8,126
-3% -$1.25M 1.3% 14
2022
Q3
$36M Buy
268,324
+11,896
+5% +$1.71M 1.23% 17
2022
Q2
$39.3M Sell
256,428
-5,870
-2% -$897K 1.3% 16
2022
Q1
$42.5M Sell
262,298
-1,864
-0.7% -$271K 1.22% 18
2021
Q4
$35.8M Buy
264,162
+794
+0.3% +$93.8K 1.01% 20
2021
Q3
$28.4M Buy
263,368
+5,019
+2% +$573K 1.01% 22
2021
Q2
$29.1M Buy
258,349
+3,989
+2% +$449K 1.06% 19
2021
Q1
$27.5M Buy
254,360
+3,578
+1% +$383K 1.08% 21
2020
Q4
$26.9M Buy
250,782
+4,902
+2% +$471K 1.1% 20
2020
Q3
$21.5M Buy
245,880
+6,563
+3% +$618K 0.97% 21
2020
Q2
$23.5M Buy
239,317
+13,795
+6% +$1.21M 1.18% 15
2020
Q1
$17.2M Buy
225,522
+8,310
+4% +$708K 1.05% 21
2019
Q4
$19.2M Buy
217,212
+19,769
+10% +$1.64M 0.98% 26
2019
Q3
$15M Buy
197,443
+3,178
+2% +$218K 0.84% 30
2019
Q2
$13.8M Buy
194,265
+2,608
+1% +$205K 0.79% 33
2019
Q1
$15.4M Sell
191,657
-20,513
-10% -$1.68M 0.92% 27
2018
Q4
$19.6M Sell
212,170
-6,387
-3% -$562K 1.3% 20
2018
Q3
$20.7M Sell
218,557
-36,707
-14% -$3.48M 1.2% 19
2018
Q2
$23.7M Buy
255,264
+316
+0.1% +$30.9K 1.51% 11
2018
Q1
$24.1M Sell
254,948
-2,189
-0.9% -$240K 1.53% 9
2017
Q4
$24.9M Sell
257,137
-5,821
-2% -$549K 1.51% 11
2017
Q3
$23.4M Buy
262,958
+2,911
+1% +$222K 1.51% 9
2017
Q2
$18.9M Sell
260,047
-476
-0.2% -$32K 1.25% 18
2017
Q1
$17M Buy
260,523
+19,898
+8% +$1.25M 1.13% 20
2016
Q4
$15.1M Buy
240,625
+278
+0.1% +$17K 1.04% 22
2016
Q3
$15.2M Buy
240,347
+6,383
+3% +$413K 1.11% 20
2016
Q2
$14.5M Sell
233,964
-2
-0% -$122 1.08% 21
2016
Q1
$13.4M Buy
233,966
+30,762
+15% +$1.71M 1.05% 21
2015
Q4
$12M Sell
203,204
-8,312
-4% -$479K 0.99% 22
2015
Q3
$11.5M Sell
211,516
-4,128
-2% -$269K 1% 19
2015
Q2
$14.5M Buy
215,644
+3,424
+2% +$224K 1.14% 16
2015
Q1
$12.4M Buy
212,220
+8,405
+4% +$508K 1% 20
2014
Q4
$13.3M Sell
203,815
-4,081
-2% -$257K 1.09% 19
2014
Q3
$12M Buy
207,896
+1,022
+0.5% +$56.7K 0.95% 23
2014
Q2
$11.7M Sell
206,874
-644
-0.3% -$33.8K 0.92% 22
2014
Q1
$10.7M Sell
207,518
-1,391
-0.7% -$70.3K 0.88% 23
2013
Q4
$11M Sell
208,909
-28,227
-12% -$1.39M 0.93% 23
2013
Q3
$10.6M Sell
237,136
-1,168
-0.5% -$51.8K 0.96% 23
2013
Q2
$9.85M Buy
+238,304
New +$10.4M 0.94% 25

Other funds holding ABBV

Central Trust Company's ABBV Position: Q1 2026 in Review

Central Trust Company increased its AbbVie (ABBV) stake by 0.54% in Q1 2026, buying an estimated $256K and bringing the position to 213,747 shares worth $46.5M. The position accounts for 0.92% of the portfolio, ranked #27.

Central Trust Company first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $50.1M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Central Trust Company held 213,747 shares of AbbVie worth $46.5M as of Q1 2026.
  • Central Trust Company bought 1,153 AbbVie shares in Q1 2026, an estimated $256K.
  • AbbVie made up 0.92% of Central Trust Company's portfolio in Q1 2026, its #27 holding.
  • Central Trust Company first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Central Trust Company's AbbVie position peaked at $50.1M in Q3 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Central Trust Company's 13F filing for Q1 2026, filed 17 Apr 2026.